Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
49 /100
MEDIUM RISK
Score updated Oct 27, 2026

AVTX — Avalo Therapeutics, Inc. Dilution Risk Tracker

Track AVTX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track AVTX — Get alerts when the score changes →

As of October 27, 2026, Avalo Therapeutics, Inc. (AVTX) has a DilutionWatch DilutionScore of 49/100, rated MEDIUM dilution risk. Avalo Therapeutics, Inc. has a market capitalization of $358.78M, 53.63M shares outstanding, 101 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
80
💰 Cash Runway
0
📊 Float Risk
35
⚠️ Warrant Exposure
40
🔄 Convertible Debt
15

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for AVTX.
🔔 Track AVTX — Get forecast alerts →

Market Data

Market Cap$358.78M
Shares Outstanding53.63M
Float40.18M
Cash$400.28M
Debt$15.30M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore49/100DilutionWatch score record
Shares Outstanding53.63MVerified float table or market cache
Public Float40.18MVerified float table or market cache
Market Cap$358.78MMarket data cache
Cash Runway110.7 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 4 5, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

AVTX SEC Filing Activity — Last 12 Months

Shares outstanding reported by AVTX on the cover page of its latest 10-K/10-Q: 53.63M as of August 03, 2026.

DilutionWatch recorded 1 registration or prospectus document for AVTX (the filings through which shares are offered) in the last 12 months. Full filing list on SEC EDGAR →

FormWhat it isFilingsMost recent
S-3shelf registration1Jan 08, 2026
EFFECTSEC declared a registration effective2Jul 29, 2026
8-Kcurrent report (material event)12Aug 06, 2026
10-Kannual report1Mar 23, 2026
10-Qquarterly report2Aug 06, 2026
SC 13Gpassive >5% holder filing1Aug 07, 2026
SC 13G/Aamended passive >5% holder filing4Aug 14, 2026
3initial insider ownership58Sep 18, 2026

Institutional Holdings

QoQ: ↑ 69.3% shares (2026Q1 vs prior)
101 institutional holders · 36.04M shares
#1 FMR LLC 2.88M shares
#2 T. Rowe Price Investment Management, Inc. 2.16M shares
#3 Caligan Partners LP 1.64M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest11.96M
Days to Cover13.0
% of Float29.8%
FINRA data as of Oct 15, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-03-23
xbrl XBRL CONVERTIBLE 2026-03-23
4 INSIDER TRANSACTION 2026-04-08
4 INSIDER TRANSACTION 2026-04-03
4 INSIDER TRANSACTION 2026-04-03
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual AVTX Dilution Snapshot

Avalo Therapeutics, Inc. (AVTX) has a DilutionScore of 49/100, rated Medium dilution risk. Score date: October 27, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

AVTX's DilutionScore is currently 49/100 (Medium risk), with 2 score changes tracked over 89 days. The score deteriorated from 61/100 (High risk).

Period Score Risk Level Duration
Aug 22 – Oct 27, 202649/100MEDIUM67 days
Aug 14 – Aug 21, 202661/100HIGH7 days
Jul 30 – Aug 13, 202656/100HIGH15 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

AVTX shares outstanding have increased 183.9% from 18.51M (Mar 2026) to 52.57M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 31, 202652.57M40.18M▼ 7.07%
May 30, 202652.57M43.24M▼ 5.90%
May 28, 202652.57M45.95M▼ 0.52%
May 27, 202652.57M46.19M▲ 1.00%
May 26, 202652.57M45.74M▲ 126.84%
May 10, 202652.23M20.16M▲ 0.01%
May 03, 202622.79M20.16M▲ 0.07%
Apr 20, 202622.79M20.14M▲ 16.67%
Apr 07, 202622.79M17.27M▲ 0.09%
Apr 03, 202622.79M17.25M▼ 0.43%
Mar 28, 202622.79M17.33M▲ 27.21%
Mar 24, 202618.51M13.62M▲ 25.67%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track AVTX Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment AVTX files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking AVTX — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,566+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for AVTX
AVTX FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.